A customer complaint was received (cmp-216) which described that the factor viii antibody screen (f8s) assay results were negative (neg) and the laboratory's in-house (b)(6) assay results were positive.The ordering physician was expecting (b)(6) results ( units - bu) and contacted lab when they did not receive the bu results.The laboratories testing paradigm was to test samples on the f8s kit and if positive results (pos) were obtained, then the sample was refluxed to the (b)(6) assay.The initial customer notification was provided to manufacturer on (b)(6 )2014.After multiple requests of customer, samples were sent on (b)(6) 2014 to manufacturer.Internal testing showed that the concerned lot of product was performing as expected when using internal well-characterized samples.The (b)(6) assay is in internal lab developed test.The laboratory has changed their testing paradigm due to this information to reflux samples to the (b)(6) assay if f8s is less than 20 percent activity.
|